Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.70960 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Qiumin Luo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, Tenofovir, Hepatitis B virus. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Guangzhou Science and Technology Program Key Projects.
Abstract (Originalsprache)
Antiviral treatment for chronic HBV infection in the “high‐replicative low‐inflammatory” phase has not been widely recommended. This study aimed to evaluate the safety and efficacy of antiviral therapy in this patient population and analyze peripheral immunological characteristics in relation to treatment response. In this randomized controlled trial, HBeAg‐positive patients with normal ALT and elevated HBV DNA were randomly allocated 1:1 to receive TAF 25 mg/day or observation. The primary endpoint was the decline from baseline in HBsAg at Week 48. Secondary endpoints included HBV DNA response rates and the magnitude of HBV DNA reduction. The treatment group was further divided into virological response (VR) and low‐level viremia (LLV) subgroups based on HBV DNA response at Week 48. PBMCs from VR ( n = 3) and LLV ( n = 3) patients underwent scRNA‐seq for comparative immunological analysis. A total of 59 patients were allocated to the treatment ( n = 30) and control ( n = 29) groups. No serious adverse events occurred, except for one control patient who developed an ALT flare and required antiviral initiation. At Week 48, the treatment group demonstrated significantly greater reductions in HBsAg (0.19 vs. 0 log10 IU/mL, p = 0.005) and HBV DNA (6.32 vs. 0.19 log10 IU/mL, p < 0.001) compared to controls. In the treatment group, 20% achieved HBV DNA < 20 IU/mL and 3.3% achieved HBeAg seroconversion, while none occurred in the untreated patients. PBMCs scRNA‐seq revealed dominant distributions of NK_FCER1G, NK_KLRF1, NK_XCL1, and NKT_FCGR3A subclusters in the VR group, with upregulated expression of genes such as SLC27A4 and PTMA . Taken together, our findings revealed that TAF demonstrates favorable safety and antiviral efficacy in patients with high‐replicative, low‐inflammatory HBV infection during the 48‐week follow‐up period, although complete virological suppression rates remain suboptimal. NK‐mediated mechanisms may contribute to antiviral success. Trial Registration: The trial was registered on ClinicalTrials.gov (NCT 04231565).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Disease, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
- Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
ORCID-Profile: Wenxiong Xu, Xingrong Zheng, Chan Xie, Liang Peng
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Guangzhou Science and Technology Program Key Projects
- Guangzhou Science and Technology Program
- Sun Yat-Sen University Clinical Research 5010 Program
- Five-Year5-Year Plan of Third Affiliated Hospital of Sun Yat-sen University
Zitieren
APA
Luo, Q., Xu, R., Zhang, Y., Xu, W., Li, X., Lai, J., Li, J., Zheng, X., Deng, H., Chen, L., Zhu, X., Xie, C., & Peng, L. (2026). Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial. Journal of Medical Virology. https://doi.org/10.1002/jmv.70960
Vancouver
Luo Q, Xu R, Zhang Y, Xu W, Li X, Lai J, et al. Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial. Journal of Medical Virology. 2026. doi:10.1002/jmv.70960
BibTeX
@article{Luo2026,
author = {Luo, Qiumin and Xu, Ruixuan and Zhang, Yeqiong and Xu, Wenxiong and Li, Xiangyong and Lai, Jing and Li, Jianguo and Zheng, Xingrong and Deng, Hong and Chen, Lubiao and Zhu, Xiang and Xie, Chan and Peng, Liang},
title = {Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.70960}
}
EUVIMED